The Experts below are selected from a list of 66132 Experts worldwide ranked by ideXlab platform

Önder Gürlek - One of the best experts on this subject based on the ideXlab platform.

  • Periodontal Diseases/Treatment and Bisphosphonates
    Current Oral Health Reports, 2018
    Co-Authors: Pınar Meriç, Önder Gürlek
    Abstract:

    Purpose of Review Host response against bacteria or their toxins eventually play a major role in alveolar bone destruction observed in periodontitis. Because of the role in bone resorption, Bisphosphonates were applied as adjunct to non-surgical therapy. This review highlights the effects of Bisphosphonates on clinical parameters as adjunct to periodontal treatment. Recent Findings Significant clinical and radiographic effects were observed in animal and human study models. In recent studies, local usage of the Bisphosphonate gels was examined in periodontitis patients to prevent the systemic side effects. The mean pocket depth reduction, clinical attachment level gain, and the percentage of defect depth reduction were greater in Bisphosphonate group. Summary Bisphosphonates appear to be effective in improving clinical outcomes of periodontal treatment. However, the clinical relevance still remains controversial because of the differences in methodology in the studies. New evidences from high-quality clinical trials are required to clear the clinical application of Bisphosphonates as adjunct to non-surgical periodontal treatment in periodontitis.

  • Periodontal Diseases/Treatment and Bisphosphonates
    Current Oral Health Reports, 2018
    Co-Authors: Pınar Meriç, Önder Gürlek
    Abstract:

    Host response against bacteria or their toxins eventually play a major role in alveolar bone destruction observed in periodontitis. Because of the role in bone resorption, Bisphosphonates were applied as adjunct to non-surgical therapy. This review highlights the effects of Bisphosphonates on clinical parameters as adjunct to periodontal treatment. Significant clinical and radiographic effects were observed in animal and human study models. In recent studies, local usage of the Bisphosphonate gels was examined in periodontitis patients to prevent the systemic side effects. The mean pocket depth reduction, clinical attachment level gain, and the percentage of defect depth reduction were greater in Bisphosphonate group. Bisphosphonates appear to be effective in improving clinical outcomes of periodontal treatment. However, the clinical relevance still remains controversial because of the differences in methodology in the studies. New evidences from high-quality clinical trials are required to clear the clinical application of Bisphosphonates as adjunct to non-surgical periodontal treatment in periodontitis.

Christian Walter - One of the best experts on this subject based on the ideXlab platform.

  • Effects of an oral Bisphosphonate and three intravenous Bisphosphonates on several cell types in vitro
    Clinical Oral Investigations, 2018
    Co-Authors: Junho Jung, Bilal Al-nawas, Jung Soo Park, Leonardo Righesso, Yong-dae Kwon, Andreas Max Pabst, Christian Walter
    Abstract:

    Objective To analyze the influence of an oral Bisphosphonate and compare the potency to intravenous Bisphosphonates on various cell types as regards the rarity of Bisphosphonate-associated osteonecrosis of the jaw (BP-ONJ) caused by oral Bisphosphonate. Materials and methods A viability assay (MTT), a migration assay (Boyden chamber), and an apoptosis assay (Caspase-Glo® 3/7) were performed to analyze the effect of Bisphosphonates on human fibroblasts, umbilical vein endothelial cells (HUVEC), and osteoblasts. Results Alendronate and intravenous Bisphosphonates suppressed cell viability and migration, and induced apoptosis in all tested cell types. Alendronate had a greater impact than ibandronate on the characteristics in fibroblasts and osteoblasts but not as strong as zoledronate. Conclusions The incidence of BP-ONJ in oral Bisphosphonate treatment is reported to be much lower than that in intravenous Bisphosphonates. However, the influences of alendronate on human cells were at least as strong as ibandronate, although it was lower than zoledronate. Clinical relevance Alendronate showed strong enough effects to suppress human somatic cells and was comparable to certain intravenous Bisphosphonates in potency. This study suggests that the lower incidence of BP-ONJ in alendronate treatment is not originated by its potency, but might be due to the low bioavailability of alendronate, lower dosing on a daily basis, and having no additional therapies.

  • Effects of an oral Bisphosphonate and three intravenous Bisphosphonates on several cell types in vitro.
    Clinical oral investigations, 2018
    Co-Authors: Junho Jung, Bilal Al-nawas, Jung Soo Park, Leonardo Righesso, Andreas Pabst, Yong-dae Kwon, Christian Walter
    Abstract:

    Objective To analyze the influence of an oral Bisphosphonate and compare the potency to intravenous Bisphosphonates on various cell types as regards the rarity of Bisphosphonate-associated osteonecrosis of the jaw (BP-ONJ) caused by oral Bisphosphonate.

  • In vitro effects of Bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes
    Clinical Oral Investigations, 2014
    Co-Authors: Nadine Hagelauer, Andreas Pabst, Thomas Ziebart, Holger Ulbrich, Christian Walter
    Abstract:

    Objectives Bisphosphonate-associated osteonecrosis of the jaws is a serious side effect that mainly occurs in patients receiving highly potent, nitrogen-containing Bisphosphonates. Usually the diagnosis is made due to exposed bone and a nonhealing wound. Neutrophil granulocytes are essential for sufficient wound healing; therefore, the influence of different Bisphosphonates on neutrophil granulocytes was the focus of this study.

  • Bisphosphonates restrictions for vasculogenesis and angiogenesis inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro
    Clinical Oral Investigations, 2011
    Co-Authors: Thomas Ziebart, Andreas Pabst, Marcus Oliver Klein, Peer W Kammerer, Leonie Gauss, Dan Brullmann, Bilal Alnawas, Christian Walter
    Abstract:

    Bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) is one of the main side effects in patients treated with Bisphosphonates for metastasis to the bone or osteoporosis. BP-ONJ usually occurs in patients treated with highly potent nitrogen-containing Bisphosphonates. The exact mechanism of action and etiopathology is still unknown. In addition to inhibition of bone remodelling, an anti-angiogenetic effect has become the focus of research. The aim of these study was to investigate the effect of different Bisphosphonates on human umbilicord vein endothelial cells (HUVEC) and endothelial progenitor cells (EPC), which play an important role in angiogenesis. Using varying concentrations, the impact of one non-nitrogen-containing Bisphosphonate (clodronate) and three nitrogen-containing Bisphosphonates (ibandronate, pamidronate and zoledronate) on HUVEC and EPC was analysed. The biologic behaviour of HUVEC after incubation with different Bisphosphonates was measured in a Boyden migration assay as well as in a 3D angiogenesis assay. The number of apoptotic cells was measured by Tunnel assay. To underline the importance of neoangiogenesis in the context of BP-ONJ, we measured the EPC number after incubation with different Bisphosphonates in vitro. HUVEC and EPC were significantly influenced by Bisphosphonates at different concentrations compared with the non-treated control groups. The nitrogen-containing Bisphosphonates pamidronate and zoledronate had the greatest impact on the cells, whereas clodronate followed by ibandronate was less distinct on cell function. These results underline the hypothesis that inhibited angiogenesis induced by Bisphosphonates might be of relevance in the development and maintenance of BP-ONJ. The increased impact by highly potent Bisphosphonates on HUVEC and EPC may explain the high prevalence of BP-ONJ in patients undergoing this treatment.

  • Bisphosphonates affect migration ability & cell viability of HUVEC, fibroblasts and osteoblasts in-vitro
    Oral Diseases, 2010
    Co-Authors: Christian Walter, Andreas Pabst, Thomas Ziebart, Marcus Oliver Klein, B Al-nawas
    Abstract:

    Objective: Bisphosphonate-associated-osteonecrosis of the jaw (BP-ONJ) is a side effect in patients being treated with Bisphosphonates. The Bisphosphonates most often associated with BP-ONJ are the highly potent nitrogen-containing Bisphosphonates e.g. pamidronate or zoledronate. In terms of BP-ONJ aetiology, several theories are being discussed: inhibition of bone remodelling, effect on soft tissues, and antiangiogenic effect of Bisphosphonates. The aim of this in-vitro study was to investigate the effect of different potent Bisphosphonates on osteoblasts, fibroblasts and human umbilicord vein endothelial cells (HUVEC). Materials and Methods: Three nitrogen-containing Bisphosphonates (ibandronate, pamidronate and zoledronate) and one non-nitrogen-containing Bisphosphonate (clodronate) were compared concerning their potency on apoptosis induction (tunnel), cell viability (calcein assay) and migration potency (boyden chamber) on osteoblasts, fibroblasts and HUVEC. Results: The nitrogen-containing bisphphosphonates, particularly pamidronate and zoledronate, affect cell viability, cell migration and the induction of apoptosis of osteoblasts, fibroblasts and HUVEC. Conclusions: These results support the theory that BP-ONJ is a multifactorially caused disease because several cell lines of the oral cavity which are responsible for integrity and wound healing are negatively affected by nitrogen-containing Bisphosphonates. Perioperative interruption of Bisphosphonate application during dental surgical procedures - if possible - might be feasible to promote better wound healing.

Pınar Meriç - One of the best experts on this subject based on the ideXlab platform.

  • Periodontal Diseases/Treatment and Bisphosphonates
    Current Oral Health Reports, 2018
    Co-Authors: Pınar Meriç, Önder Gürlek
    Abstract:

    Purpose of Review Host response against bacteria or their toxins eventually play a major role in alveolar bone destruction observed in periodontitis. Because of the role in bone resorption, Bisphosphonates were applied as adjunct to non-surgical therapy. This review highlights the effects of Bisphosphonates on clinical parameters as adjunct to periodontal treatment. Recent Findings Significant clinical and radiographic effects were observed in animal and human study models. In recent studies, local usage of the Bisphosphonate gels was examined in periodontitis patients to prevent the systemic side effects. The mean pocket depth reduction, clinical attachment level gain, and the percentage of defect depth reduction were greater in Bisphosphonate group. Summary Bisphosphonates appear to be effective in improving clinical outcomes of periodontal treatment. However, the clinical relevance still remains controversial because of the differences in methodology in the studies. New evidences from high-quality clinical trials are required to clear the clinical application of Bisphosphonates as adjunct to non-surgical periodontal treatment in periodontitis.

  • Periodontal Diseases/Treatment and Bisphosphonates
    Current Oral Health Reports, 2018
    Co-Authors: Pınar Meriç, Önder Gürlek
    Abstract:

    Host response against bacteria or their toxins eventually play a major role in alveolar bone destruction observed in periodontitis. Because of the role in bone resorption, Bisphosphonates were applied as adjunct to non-surgical therapy. This review highlights the effects of Bisphosphonates on clinical parameters as adjunct to periodontal treatment. Significant clinical and radiographic effects were observed in animal and human study models. In recent studies, local usage of the Bisphosphonate gels was examined in periodontitis patients to prevent the systemic side effects. The mean pocket depth reduction, clinical attachment level gain, and the percentage of defect depth reduction were greater in Bisphosphonate group. Bisphosphonates appear to be effective in improving clinical outcomes of periodontal treatment. However, the clinical relevance still remains controversial because of the differences in methodology in the studies. New evidences from high-quality clinical trials are required to clear the clinical application of Bisphosphonates as adjunct to non-surgical periodontal treatment in periodontitis.

Jeroen P. Jansen - One of the best experts on this subject based on the ideXlab platform.

  • Indirect comparison of bazedoxifene vs oral Bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women
    Current medical research and opinion, 2014
    Co-Authors: Alexandra G. Ellis, Jean-yves Reginster, Xuemei Luo, Andrew G. Bushmakin, Robert Williams, Santosh Sutradhar, Sebastian Mirkin, Jeroen P. Jansen
    Abstract:

    AbstractObjective:Compare the efficacy of bazedoxifene with oral Bisphosphonates for reduction of vertebral fracture risk in postmenopausal osteoporotic (PMO) women and in higher-risk patients based on evidence from randomized controlled trials (RCTs).Methods:Eight RCTs assessing vertebral fracture risk reduction with oral Bisphosphonates (n = 7) or bazedoxifene (n = 1) were identified by a systematic literature review. Individual study results were pooled in a network meta-analysis (NMA) to indirectly compare treatment effects for overall PMO women and a higher-risk subgroup (FRAX ≥ 20%). Three sets of NMA analyses were conducted: aggregate data (AD) from the Bisphosphonate RCTs and bazedoxifene RCT for the full population or the FRAX ≥20% subgroup (NMA AD); Bisphosphonate AD and bazedoxifene AD from each FRAX subgroup adjusted for baseline risk (NMA AD meta-regression); and Bisphosphonate AD and bazedoxifene individual patient data (IPD) adjusted for baseline risk/FRAX (NMA AD/IPD meta-regression).Resul...

Joseph M Lane - One of the best experts on this subject based on the ideXlab platform.

  • atypical fracture with long term Bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance
    Proceedings of the National Academy of Sciences of the United States of America, 2017
    Co-Authors: Ashley A Lloyd, Bernd Gludovatz, Christoph Riedel, Emma A Luengo, Rehan Saiyed, Eric Marty, Dean G Lorich, Joseph M Lane
    Abstract:

    Bisphosphonates are the most widely prescribed pharmacologic treatment for osteoporosis and reduce fracture risk in postmenopausal women by up to 50%. However, in the past decade these drugs have been associated with atypical femoral fractures (AFFs), rare fractures with a transverse, brittle morphology. The unusual fracture morphology suggests that Bisphosphonate treatment may impair toughening mechanisms in cortical bone. The objective of this study was to compare the compositional and mechanical properties of bone biopsies from Bisphosphonate-treated patients with AFFs to those from patients with typical osteoporotic fractures with and without Bisphosphonate treatment. Biopsies of proximal femoral cortical bone adjacent to the fracture site were obtained from postmenopausal women during fracture repair surgery (fracture groups, n = 33) or total hip arthroplasty (nonfracture groups, n = 17). Patients were allocated to five groups based on fracture morphology and history of Bisphosphonate treatment [+BIS Atypical: n = 12, BIS duration: 8.2 (3.0) y; +BIS Typical: n = 10, 7.7 (5.0) y; +BIS Nonfx: n = 5, 6.4 (3.5) y; -BIS Typical: n = 11; -BIS Nonfx: n = 12]. Vibrational spectroscopy and nanoindentation showed that tissue from Bisphosphonate-treated women with atypical fractures was harder and more mineralized than that from Bisphosphonate-treated women with typical osteoporotic fractures. In addition, fracture mechanics measurements showed that tissue from patients treated with Bisphosphonates had deficits in fracture toughness, with lower crack-initiation toughness and less crack deflection at osteonal boundaries than that of Bisphosphonate-naive patients. Together, these results suggest a deficit in intrinsic and extrinsic toughening mechanisms, which contribute to AFFs in patients treated with long-term Bisphosphonates.